|
RGPD3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.03430042308617E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.88909999865317E-08 |
| Normal-vs-Stage2 |
3.50650000002783E-06 |
| Normal-vs-Stage3 |
2.9644999788303E-09 |
| Normal-vs-Stage4 |
7.12909997702127E-09 |
| Stage1-vs-Stage2 |
6.270800E-01 |
| Stage1-vs-Stage3 |
1.909190E-01 |
| Stage1-vs-Stage4 |
8.892100E-02 |
| Stage2-vs-Stage3 |
6.563000E-01 |
| Stage2-vs-Stage4 |
4.494200E-01 |
| Stage3-vs-Stage4 |
6.860600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.02149979983335E-10 |
| Normal-vs-AfricanAmerican |
1.295820E-02 |
| Normal-vs-Asian |
8.85369999981123E-07 |
| Caucasian-vs-AfricanAmerican |
1.465150E-01 |
| Caucasian-vs-Asian |
8.124600E-01 |
| AfricanAmerican-vs-Asian |
1.404040E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.73000003211854E-09 |
| Normal-vs-Female |
1.01990005330066E-09 |
| Male-vs-Female |
6.174400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.38949999950455E-07 |
| Normal-vs-Age(41-60Yrs) |
1.16910003900017E-09 |
| Normal-vs-Age(61-80Yrs) |
9.49129996818954E-09 |
| Normal-vs-Age(81-100Yrs) |
1.037720E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.036200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.156600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.891600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.749000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.949400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.477600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.182600E-04 |
| Classical-VS-Follicular |
4.216400E-02 |
| Classical-VS-Other |
3.484600E-01 |
| Classical-VS-Normal |
3.99570000420013E-08 |
| Tall-VS-Follicular |
1.673650E-01 |
| Tall-VS-Other |
5.865400E-01 |
| Tall-VS-Normal |
5.73230019007553E-10 |
| Follicular-VS-Other |
8.335000E-01 |
| Follicular-VS-Normal |
5.10590000279976E-08 |
| Other-VS-Normal |
5.223800E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.11460010297083E-10 |
| Normal-vs-N1 |
4.2427000002121E-07 |
| N0-vs-N1 |
8.002200E-01 |
|
|
